Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Molecules ; 28(23)2023 Dec 03.
Article in English | MEDLINE | ID: mdl-38067642

ABSTRACT

(1) Background: almond peels are rich in polyphenols such as catechin and epicatechin, which are important anti-free-radical agents, anti-inflammatory compounds, and capable of breaking down cholesterol plaques. This work aims to evaluate the biological and technological activity of a "green" dry aqueous extract from Sicilian almond peels, a waste product of the food industry, and to develop healthy nutraceuticals with natural ingredients. Eudraguard® Natural is a natural coating polymer chosen to develop atomized formulations that improve the technological properties of the extract. (2) Methods: the antioxidant and free radical scavenger activity of the extract was rated using different methods (DPPH assay, ABTS, ORAC, NO). The metalloproteinases of the extracts (MMP-2 and MMP-9), the enhanced inhibition of the final glycation products, and the effects of the compounds on cell viability were also tested. All pure materials and formulations were characterized using UV, HPLC, FTIR, DSC, and SEM methods. (3) Results: almond peel extract showed appreciable antioxidant and free radical activity with a stronger NO inhibition effect, strong activity on MMP-2, and good antiglycative effects. In light of this, a food supplement with added health value was formulated. Eudraguard® Natural acted as a swelling substrate by improving extract solubility and dissolution/release (4) Conclusions: almond peel extract has significant antioxidant activity and MMP/AGE inhibition effects, resulting in an optimal candidate to formulate safe microsystems with potential antimetabolic activity. Eudraguard® Natural is capable of obtaining spray-dried microsystems with an improvement in the extract's biological and technological characteristics. It also protects the dry extract from degradation and oxidation, prolonging the shelf life of the final product.


Subject(s)
Antioxidants , Prunus dulcis , Antioxidants/pharmacology , Antioxidants/chemistry , Matrix Metalloproteinase 2 , Plant Extracts/pharmacology , Plant Extracts/chemistry , Dietary Supplements , Free Radicals/chemistry
2.
Future Med Chem ; 11(11): 1245-1258, 2019 06.
Article in English | MEDLINE | ID: mdl-30974972

ABSTRACT

Aim: Despite the serious side effects, analgesics acting on opioid receptors are still considered the best way to get antinociception. Matrix metalloproteinases, a large family of zinc-dependent proteases implicated in many pathological conditions, such as diabetes and osteoarthritis, are also involved in inflammation and pain. Methodology & results: Looking for evidence of possible interactions of opioid pathways and inflammation mediators, molecular modeling studies of a series of recently developed µ-opioid receptor benzomorphanic agonists together with biological data on pain and inflammation molecular targets, allowed us to hypothesize a possible correlation between µ-opioid receptor system and MMP-9. Conclusion: A new compound, (-)-MML1017, emerged as a possible dual-acting agent able to interact selectively and potently with the two molecular targets.


Subject(s)
Analgesics/pharmacology , Benzomorphans/pharmacology , Matrix Metalloproteinase 9/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology , Receptors, Opioid, mu/agonists , Analgesics/chemistry , Benzomorphans/chemistry , Drug Discovery , HEK293 Cells , Humans , Matrix Metalloproteinase 9/chemistry , Matrix Metalloproteinase Inhibitors/chemistry , Models, Molecular
3.
Planta Med ; 85(3): 258-265, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30206907

ABSTRACT

Crocin and crocetin are two interesting constituents of saffron (Crocus sativus) that possess important biological activities. Their use as therapeutic agents is strongly compromised by a scarce stability, poor absorption, and low bioavailability. Therefore, to improve these unfavorable features, the aim of the present work has been to apply a nanotechnological approach based on the formulation of solid lipid nanoparticles containing crocin and crocetin. Solid lipid nanoparticles were formulated according to crocin and crocetin chemical properties, using a variation of the quasi-emulsion solvent diffusion method to formulate crocin-solid lipid nanoparticles, while crocetin-solid lipid nanoparticles were prepared following the solvent diffusion method. Morphology and dimensional distribution of solid lipid nanoparticles have been characterized by differential scanning calorimetry and photon correlation spectroscopy, respectively, while the effect of drug incorporation versus time has been studied by Turbiscan technology. In order to verify the role of the nanotechnological approach on the biological activities of crocin and crocetin, the antioxidant and antiproliferative effects of these carotenoids once incorporated in lipid nanoparticles have been evaluated. For this aim, the oxygen radical absorbance capacity assay and the MTT test were used, respectively.The results pointed out the formulation of nanometric dispersions endowed with high homogeneity and stability, with an encapsulation efficiency ranging from 80 (crocetin-solid lipid nanoparticles) to 94% (crocin-crocetin). The oxygen radical absorbance capacity assay evidenced an interesting and prolonged antioxidant activity of crocin and crocetin once encapsulated in solid lipid nanoparticles, while the nanoencapsulation strategy showed a different mechanism in ameliorating the cytotoxic effect of these two substances.


Subject(s)
Antioxidants/administration & dosage , Carotenoids/administration & dosage , Cytotoxins/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Antioxidants/pharmacokinetics , Biological Availability , Carotenoids/pharmacokinetics , Cell Line, Tumor , Cytotoxins/pharmacokinetics , Drug Delivery Systems , Humans , Nanoparticles , Vitamin A/analogs & derivatives
4.
Nanomaterials (Basel) ; 9(1)2018 Dec 29.
Article in English | MEDLINE | ID: mdl-30597985

ABSTRACT

Idebenone (IDE), a strong antioxidant widely investigated for the treatment of neurodegenerative diseases and skin disorders, shows low oral and topical bioavailability due to its unfavorable physico-chemical properties. In this work, to improve IDE topical effectiveness, we explored a two-steps approach: (1) we synthesized an IDE ester (IDEPCA) with pyroglutamic acid, a molecule whose hydrating effects are well known; (2) we loaded IDEPCA into solid lipid nanocarriers (SLN). We evaluated in vitro antioxidant and anti-glycation activity and in vivo hydrating effects after topical application in human volunteers from gel vehicles of IDEPCA SLN in comparison to IDE SLN. All SLN showed good technological properties (mean particle size < 25 nm, polydispersity index < 0.300, good stability). The oxygen radical absorbance capacity assay showed that IDEPCA SLN and IDE SLN had similar antioxidant activity while IDEPCA SLN were more effective in the in vitro NO scavenging assay. Both IDEPCA and IDE SLN showed the same effectiveness in inhibiting the formation of advanced glycation end products. In vivo experiments pointed out a better hydrating effect of IDEPCA SLN in comparison to IDE SLN. These results suggest that the investigated approach could be a promising strategy to obtain topical formulations with increased hydrating effects.

5.
Oxid Med Cell Longev ; 2017: 2867630, 2017.
Article in English | MEDLINE | ID: mdl-29230268

ABSTRACT

Alginate and ß-cyclodextrin were used to produce easily dosable and spray-dried microsystems of a dried blood orange extract with antidysmetabolic properties, obtained from a by-product fluid extract. The spray-dried applied conditions were able to obtain a concentrate dried extract without the loss of AOA and with TPC and TMA values of 35-40% higher than that of the starting material. They were also effective in producing microparticles with 80-100% of encapsulation efficiency. The 2% sodium alginate was capable of improving the extract shelf life, while the beta-cyclodextrin (1 : 1 molar ratio with dried extract) prolonged the extract antioxidant efficiency by 6 hours. The good inhibition effect of the dried extract on the AGE formation and the MMP-2 and MMP-9 activity is presumably due to a synergic effect exerted by both anthocyanin and bioflavonoid extract compounds and was improved by the use of alginate and cyclodextrin.


Subject(s)
Alginates/metabolism , Antioxidants/therapeutic use , Citrus sinensis/chemistry , Matrix Metalloproteinase Inhibitors/therapeutic use , Plant Extracts/chemistry , Polyphenols/metabolism , Antioxidants/pharmacology , Glucuronic Acid/metabolism , Hexuronic Acids/metabolism , Matrix Metalloproteinase Inhibitors/pharmacology
6.
Molecules ; 22(6)2017 May 27.
Article in English | MEDLINE | ID: mdl-28555014

ABSTRACT

Idebenone (IDE) has been proposed for the treatment of neurodegenerative diseases involving mitochondria dysfunctions. Unfortunately, to date, IDE therapeutic treatments have not been as successful as expected. To improve IDE efficacy, in this work we describe a two-step approach: (1) synthesis of IDE ester derivatives by covalent linking IDE to other two antioxidants, trolox (IDETRL) and lipoic acid (IDELIP), to obtain a synergic effect; (2) loading of IDE, IDETRL, or IDELIP into solid lipid nanoparticles (SLN) to improve IDE and its esters' water solubility while increasing and prolonging their antioxidant activity. IDE and its derivatives loaded SLN showed good physico-chemical and technological properties (spherical shape, mean particle sizes 23-25 nm, single peak in the size distribution, ζ potential values -1.76/-2.89 mV, and good stability at room temperature). In vitro antioxidant activity of these SLN was evaluated in comparison with free drugs by means of oxygen radical absorbance capacity (ORAC) test. IDETRL and IDELIP showed a greater antioxidant activity than IDE and encapsulation of IDE and its derivatives into SLN was able to prolong their antioxidant activity. These results suggest that loading IDETRL and IDELIP into SLN could be a useful strategy to improve IDE efficacy.


Subject(s)
Antioxidants/chemistry , Lipids/chemistry , Nanoparticles/chemistry , Ubiquinone/analogs & derivatives , Particle Size , Thioctic Acid/chemistry , Ubiquinone/chemistry
7.
Oxid Med Cell Longev ; 2017: 7503240, 2017.
Article in English | MEDLINE | ID: mdl-28367273

ABSTRACT

The aim of this study was to evaluate the antidegenerative effect in osteoarthritis damage of eriocitrin alone and eriocitrin formulated as innovative "dietary flavonoid supplement." A complexation between eriocitrin and hydroxypropyl ß-cyclodextrin by solubilization/freeze-drying method was performed. The complex in solution was evaluated by phase solubility studies and the optimal 1 : 2 flavanone/cyclodextrin molar ratio was selected. Hydroxypropyl ß-cyclodextrin was able to complex eriocitrin as confirmed by UV-Vis absorption, DSC, and FTIR studies. The complex formed increased the eriocitrin water solubility (from 4.1 ± 0.2 g·L-1 to 11.0 ± 0.1 g·L-1) and dissolution rate (from 37.0% to 100%) in 30 min. The in vitro studies exhibit the notion that eriocitrin and its complex inhibit AGEs in a similar manner because hydroxypropyl ß-cyclodextrin does not interfere with the flavanone intrinsic property. Instead, the presence of cyclodextrin improves eriocitrin antioxidant stability maintaining a high fluorescence value until 8 hours with respect to the pure materials. Moreover, hydroxypropyl ß-cyclodextrin showed moderate GAGs restoration acting synergistically with the complexed compound to maintain the structural chondrocytes integrity. The results point out that ERT/HP-betaCD complex possesses technological and biological characteristics able to obtain an easily soluble nutraceutical product, which reduces the degenerative and oxidative damage which occurs in osteoarthritis, and improve the patient compliance.


Subject(s)
Dietary Supplements , Flavonoids/pharmacology , Oxidative Stress/drug effects , 2-Hydroxypropyl-beta-cyclodextrin , Adult , Calorimetry, Differential Scanning , Cell Survival/drug effects , Cells, Cultured , Chondrocytes/cytology , Chondrocytes/metabolism , Drug Compounding , Flavanones/chemistry , Flavanones/pharmacology , Flavanones/therapeutic use , Flavonoids/chemistry , Flavonoids/therapeutic use , Humans , Osteoarthritis/metabolism , Osteoarthritis/pathology , Osteoarthritis/prevention & control , Solubility , Spectrophotometry, Ultraviolet , Spectroscopy, Fourier Transform Infrared , beta-Cyclodextrins/chemistry
8.
Hematol Oncol ; 35(1): 94-100, 2017 Mar.
Article in English | MEDLINE | ID: mdl-25641487

ABSTRACT

Acute promyelocytic leukaemia (APL) is a hematologic malignancy characterized by the rearrangement of the PML and RARα genes, mostly due to a reciprocal chromosomal translocation t(15;17)(q24;q21). A quick APL diagnosis is essential for starting a prompt suitable therapy. We describe a new rapid diagnostic laboratory approach to detect the PML-RARα rearrangement, which gives clear genetic results within 30 min of hybridization. It combines quick cell harvesting, fluorescence in situ hybridization performed with commercial DNA probe and microwave beams supplied by a domestic microwave oven. Copyright © 2015 John Wiley & Sons, Ltd.


Subject(s)
Chromosomes, Human, Pair 15 , Chromosomes, Human, Pair 17 , Leukemia, Promyelocytic, Acute/genetics , Oncogene Proteins, Fusion/genetics , Translocation, Genetic , DNA Probes , DNA, Neoplasm/analysis , Female , Gene Rearrangement , Humans , Immunophenotyping , In Situ Hybridization , In Situ Hybridization, Fluorescence , Karyotyping , Male , Microwaves
9.
Mater Sci Eng C Mater Biol Appl ; 71: 669-677, 2017 Feb 01.
Article in English | MEDLINE | ID: mdl-27987758

ABSTRACT

Crocin, a potent antioxidant obtained from saffron, shows anticancer activity in in vivo models. Unfortunately unfavorable physicochemical features compromise its use in topical therapy. The present study describes the preparation and characterization of nanostructured lipid dispersions as drug delivery systems for topical administration of crocin and the evaluation of antioxidant and antiproliferative effects of crocin once encapsulated into nanostructured lipid dispersions. Nanostructured lipid dispersions based on monoolein in mixture with sodium cholate and sodium caseinate have been characterized by cryo-TEM and PCS. Crocin permeation was evaluated in vitro by Franz cells, while the oxygen radical absorbance capacity assay was used to evaluate the antioxidant activity. Furthermore, the antiproliferative activity was tested in vitro by the MTT test using a human melanoma cell line. The emulsification of monoolein with sodium cholate and sodium caseinate led to dispersions of cubosomes, hexasomes, sponge systems and vesicles, depending on the employed emulsifiers. Permeation and shelf life studies demonstrated that nanostructured lipid dispersions enabled to control both rate of crocin diffusion through the skin and crocin degradation. The oxygen radical absorbance capacity assay pointed out an interesting and prolonged antioxidant activity of crocin while the MTT test showed an increase of crocin cytotoxic effect after incorporation in nanostructured lipid dispersions. This work has highlighted that nanostructured lipid dispersions can protect the labile molecule crocin from degradation, control its skin diffusion and prolong antioxidant activity, therefore suggesting the suitability of nanostructured lipid dispersions for crocin topical administration.


Subject(s)
Antioxidants , Carotenoids , Crocus/chemistry , Drug Delivery Systems/methods , Melanoma/drug therapy , Administration, Topical , Antioxidants/chemistry , Antioxidants/pharmacology , Carotenoids/chemistry , Carotenoids/pharmacology , Caseins/chemistry , Caseins/pharmacology , Cell Line, Tumor , Emulsions , Glycerides/chemistry , Glycerides/pharmacology , Humans , Melanoma/metabolism , Melanoma/pathology , Sodium Cholate/chemistry , Sodium Cholate/pharmacology
10.
Planta Med ; 83(5): 398-404, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27124246

ABSTRACT

Sesamol is a natural phenolic compound extracted from Sesamum indicum seed oil. Sesamol is endowed with several beneficial effects, but its use as a topical agent is strongly compromised by unfavorable chemical-physical properties. Therefore, to improve its characteristics, the aim of the present work was the formulation of nanostructured lipid carriers as drug delivery systems for topical administration of sesamol.Two different nanostructured lipid carrier systems have been produced based on the same solid lipid (Compritol® 888 ATO) but in a mixture with two different kinds of oil phase such as Miglyol® 812 (nanostructured lipid carrier-M) and sesame oil (nanostructured lipid carrier-PLUS). Morphology and dimensional distribution of nanostructured lipid carriers have been characterized by differential scanning calorimetry and photon correlation spectroscopy, respectively. The release pattern of sesamol from nanostructured lipid carriers was evaluated in vitro determining drug percutaneous absorption through excised human skin. Furthermore, an oxygen radical absorbance capacity assay was used to determine their antioxidant activity.From the results obtained, the method used to formulate nanostructured lipid carriers led to a homogeneous dispersion of particles in a nanometric range. Sesamol has been encapsulated efficiently in both nanostructured lipid carriers, with higher encapsulation efficiency values (> 90 %) when sesame oil was used as the oil phase (nanostructured lipid carrier-PLUS). In vitro evidences show that nanostructured lipid carrier dispersions were able to control the rate of sesamol diffusion through the skin, with respect to the reference formulations.Furthermore, the oxygen radical absorbance capacity assay pointed out an interesting and prolonged antioxidant activity of sesamol, especially when vehiculated by nanostructured lipid carrier-PLUS.


Subject(s)
Antioxidants/administration & dosage , Benzodioxoles/administration & dosage , Nanostructures , Pharmaceutical Vehicles , Phenols/administration & dosage , Administration, Topical , Adult , Antioxidants/pharmacology , Benzodioxoles/chemistry , Benzodioxoles/pharmacology , Humans , In Vitro Techniques , Lipids , Molecular Structure , Particle Size , Phenols/chemistry , Phenols/pharmacology , Skin Absorption
11.
J Pharm Sci ; 102(7): 2349-61, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23686742

ABSTRACT

Curcumin (CUR) is a well-known natural compound showing antioxidant, anti-inflammatory, and antitumor abilities but characterized by poor bioavailability and chemical instability, which drastically reduce its application in the treatment of chronic diseases such as osteoarthritis. The aim of the present study is the design and evaluation of monooleine aqueous dispersion (MAD) as novel carriers for the topical administration of CUR. CUR-loaded MAD was formulated using two different emulsifier systems, namely poloxamer 407 (MAD-A) and sodium cholate-sodium caseinate (MAD-B). These vehicles were characterized, and their influence on in vitro percutaneous absorption of CUR was also evaluated. Furthermore, an oxygen radical absorbance capacity assay was used to determine their antioxidant activity, and a Western blot analysis was performed to evaluate the inhibitory effect of the formulations on inducible nitric oxide synthase and cyclooxygenase 2 expressions. From the obtained results, CUR encapsulation efficiency was higher than 98% for MAD-A and 82% for MAD-B. Shelf-life studies showed that MAD-A maintains CUR stability better than MAD-B, and both vehicles demonstrated, in vitro, control of drug diffusion through the skin. Finally, MAD-A and MAD-B were able to extend the antioxidant/anti-inflammatory effects of CUR, also confirming the protective effect toward CUR chemical stability.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antioxidants/administration & dosage , Curcumin/administration & dosage , Drug Carriers/chemistry , Glycerides/chemistry , Skin/metabolism , Administration, Topical , Adult , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacokinetics , Antioxidants/pharmacology , Caseins/chemistry , Curcumin/pharmacokinetics , Curcumin/pharmacology , Emulsifying Agents/chemistry , Humans , Poloxamer/chemistry , Skin Absorption , Sodium Cholate/chemistry , Water/chemistry
12.
Calcif Tissue Int ; 90(4): 272-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22322409

ABSTRACT

A follow-up program to help patients suffering from severe osteoporosis during their therapy with teriparatide or PTH(1-84) has been designed and performed. The objective of this study was to evaluate the 18-month persistence on these therapies in patients participating in the program. We enrolled 382 patients who started teriparatide or PTH(1-84) following this program and compared them with a historical cohort of 398 patients treated with the same therapies but who did not participate in any follow-up program. At the beginning of the therapy, nurses trained patients on self-injection. Patients received one phone call per week during the first month, then one phone call per month and per 3 months during the following 5 and 12 months, respectively. In every call, nurses helped patients to resolve any possible issues and collected adverse event information. The persistence rate of the group following the program was 85.6%, 8.2% higher than that of the group not following any program (77.4%). The log-rank test on persistence rates on therapy in patients enrolled and not enrolled in the program was performed; the difference was statistically significant (P = 0.006). Discontinuation in the follow-up program group occurred mainly at early stages of the treatment due to adverse events. Our results show that patients suffering from severe osteoporosis treated with teriparatide or PTH(1-84) and enrolled in a follow-up program have higher persistence rates than patients not following the program.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Parathyroid Hormone/therapeutic use , Teriparatide/therapeutic use , Aged , Bone Density , Bone Density Conservation Agents/administration & dosage , Female , Follow-Up Studies , Humans , Male , Parathyroid Hormone/administration & dosage , Telephone , Teriparatide/administration & dosage
13.
World J Orthop ; 3(11): 190-8, 2012 Nov 18.
Article in English | MEDLINE | ID: mdl-23330074

ABSTRACT

The relation between bone remodelling and energy expenditure is an intriguing, and yet unexplained, challenge of the past ten years. In fact, it was only in the last few years that the skeleton was found to function, not only in its obvious roles of body support and protection, but also as an important part of the endocrine system. In particular, bone produces different hormones, like osteocalcin (OC), which influences energy expenditure in humans. The undercarboxylated form of OC has a reduced affinity for hydroxyapatite; hence it enters the systemic circulation more easily and exerts its metabolic functions for the proliferation of pancreatic ß-cells, insulin secretion, sensitivity, and glucose tolerance. Leptin, a hormone synthesized by adipocytes, also has an effect on both bone remodelling and energy expenditure; in fact it inhibits appetite through hypothalamic influence and, in bone, stimulates osteoblastic differentiation and inhibits apoptosis. Leptin and serotonin exert opposite influences on bone mass accrual, but several features suggest that they might operate in the same pathway through a sympathetic tone. Serotonin, in fact, acts via two opposite pathways in controlling bone remodelling: central and peripheral. Serotonin product by the gastrointestinal tract (95%) augments bone formation by osteoblast, whereas brain-derived serotonin influences low bone mineral density and its decrease leads to an increase in bone resorption parameters. Finally, amylin (AMY) acts as a hormone that alters physiological responses related to feeding, and plays a role as a growth factor in bone. In vitro AMY stimulates the proliferation of osteoblasts, and osteoclast differentiation. Here we summarize the evidence that links energy expenditure and bone remodelling, with particular regard to humans.

15.
Bioorg Chem ; 39(1): 48-52, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21208635

ABSTRACT

2-Benzo[d]thiazolyl- and 2-benzo[d]isothiazolyl-imino-5-benzylidene-4-thiazolidinone derivatives were investigated as potential metalloproteinases (MMPs) inhibitors and evaluated for their antidegenerative activity on human chondrocyte cultures stimulated by IL-1ß, using an experimental model that reproduces the mechanisms involved in osteoarthritic (OA) diseases. Cell viability, the amount of glycosaminoglycans (GAGs) and the production of nitric oxide (NO) were measured. The most potent compound, 5-(4-methoxy-benzylidene)-2-(benzo[d]isothiazol-3-ylimino)-thiazolidin-4-one (4b), a MMP-13 inhibitor at nanomolar concentration (IC(50)=0.036 µM), could be considered as a lead compound for the development of novel clinical agents, inhibitors of cartilage degradation, for the treatment of OA.


Subject(s)
Cartilage/drug effects , Metalloproteases/antagonists & inhibitors , Osteoarthritis/drug therapy , Thiazolidines/chemistry , Thiazolidines/pharmacology , Cartilage/immunology , Cartilage/metabolism , Cells, Cultured , Chondrocytes/drug effects , Chondrocytes/immunology , Chondrocytes/metabolism , Glycosaminoglycans/metabolism , Humans , Interleukin-1beta/immunology , Metalloproteases/metabolism , Nitrogen Oxides/immunology , Osteoarthritis/immunology , Osteoarthritis/metabolism
16.
Bioorg Med Chem ; 15(24): 7618-25, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17889545

ABSTRACT

5-Arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones (7,8) were synthesized and evaluated for their antidegenerative activity on human chondrocyte cultures stimulated by IL-1beta. This in vitro model has proven to be a useful experimental model to reproduce the mechanisms involved in arthritic diseases. The cell viability, the amount of GAGs, the production of NO and PGE(2) and the inhibition of MMP-3 were measured. Several thiazolidinones 7 and 8 exhibited the ability to block the production or action of the degenerative factors induced by IL-1beta.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Chondrocytes/drug effects , Imines/chemical synthesis , Models, Biological , Thiazolidines/chemical synthesis , Thiazolidines/pharmacology , Arthritis/drug therapy , Cell Survival/drug effects , Cells, Cultured , Chondrocytes/immunology , Drug Evaluation, Preclinical , Humans , Imines/pharmacology , Indomethacin/pharmacology , Interleukin-1beta/pharmacology , Reference Standards
17.
ChemMedChem ; 2(1): 113-9, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17131461

ABSTRACT

New derivatives of N-benzo[d]isothiazol-3-yl-benzamidine 6 a were synthesized as nonacidic anti-inflammatory/antidegenerative agents. We investigated the influence of the amidines 6 a-j on the production of NO, PGE(2), MMP-3, COX-2, ROS, and GAGs, key molecules involved in cartilage destruction in osteoarthritic diseases. The antidegenerative properties of the novel designed derivatives 6 b-j were improved with respect to N-benzo[d]isothiazol-3-yl-benzamidine 6 a. All of the compounds 6 a-j promoted the reduction of most of the IL-1beta-induced harmful effects. Derivatives 6 d, 6 h, and 6 j were the most potent of all the tested compounds, particularly in the human chondrocyte culture model.


Subject(s)
Amidines/chemistry , Anti-Inflammatory Agents/therapeutic use , Benzamidines/pharmacology , Cartilage/drug effects , Chondrocytes/drug effects , Interleukin-1beta/pharmacology , Osteoarthritis/drug therapy , Protective Agents/therapeutic use , Anti-Inflammatory Agents/chemical synthesis , Anti-Inflammatory Agents/pharmacology , Benzamidines/chemical synthesis , Cartilage/metabolism , Cells, Cultured , Chondrocytes/metabolism , Cyclooxygenase 2/metabolism , Glycosaminoglycans/metabolism , Humans , Matrix Metalloproteinase 3/metabolism , Nitric Oxide/metabolism , Protective Agents/chemical synthesis , Protective Agents/pharmacology , Reactive Oxygen Species/metabolism , Structure-Activity Relationship
18.
Bioorg Med Chem ; 11(13): 2983-9, 2003 Jul 03.
Article in English | MEDLINE | ID: mdl-12788367

ABSTRACT

A series of 2-dialkylamino-N-(4-substituted thiazolyl-2)acetamides and 3-dialkylamino-N-(4-substituted thiazolyl-2)propionamides were synthesized and evaluated for their anti-inflammatory activity. Encouraging results led us to investigate the effect of these compounds on NO production and GAGs release. Their effects were evaluated in vitro on the metabolism of pig cartilage, treated with IL-1beta. The amount of glycosaminoglycans (GAGs) and the production of nitric oxide (NO) in the culture medium were determined. The results, obtained, showed that all compounds, in the presence of IL-1beta, blocked the cartilage breakdown, with different behavior. A quantitative structure-activity relationship (QSAR) study was performed.


Subject(s)
Cartilage/drug effects , Protective Agents/chemistry , Quantitative Structure-Activity Relationship , Thiazoles/chemistry , Thiazoles/pharmacology , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , Cartilage/metabolism , Cartilage Diseases/drug therapy , Culture Techniques , Dose-Response Relationship, Drug , Glycosaminoglycans/metabolism , Interleukin-1 , Nitric Oxide/metabolism , Protective Agents/pharmacology , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...